Vaxcyte (PCVX) Amortizatization of Intangibles (2021 - 2026)
Vaxcyte (PCVX) reported Amortizatization of Intangibles of $3.1 million for Q1 2026, down 36.66% year-over-year from $4.9 million in Q1 2025, and down 62.38% quarter-over-quarter from $8.3 million in Q4 2025.
Vaxcyte (PCVX) Amortizatization of Intangibles (2021 - 2026) Analysis & Trends
Vaxcyte (PCVX) has 6 years of Amortizatization of Intangibles data on file, last reported at $3.1 million in Q1 2026.
- Amortizatization of Intangibles for Q1 2026 came in at $3.1 million, down 36.66% year-over-year; the trailing twelve-month figure through Mar 2026 was $12.6 million (up 357.05% YoY), and the FY2025 annual result was $14.4 million, up 63.24% from the prior year.
- Amortizatization of Intangibles fell to $3.1 million in Q1 2026 per PCVX's latest filing, from $8.3 million in the prior quarter.
- Over five years, Amortizatization of Intangibles peaked at $16.2 million in Q2 2023 and troughed at -$25.4 million in Q4 2023.
- A 5-year average of $2.0 million and a median of $2.1 million in 2025 frame the typical range for Amortizatization of Intangibles.
- On a YoY basis, Amortizatization of Intangibles climbed as much as 607.79% in 2023 and fell as far as 2260.94% in 2023.
- A 5-year view of Amortizatization of Intangibles shows it stood at $1.2 million in 2022, then slumped by 2260.94% to -$25.4 million in 2023, then surged by 107.57% to $1.9 million in 2024, then jumped by 330.66% to $8.3 million in 2025, then plunged by 62.38% to $3.1 million in 2026.
- Business Quant data shows PCVX's Amortizatization of Intangibles at $3.1 million in Q1 2026, $8.3 million in Q4 2025, and $2.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 13,267.00 |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | Vaxcyte | 6.34 Bn | 6.34 Bn | - | 3.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.11 Mn |
| Mar 31, 2026 | 3.11 Mn |
| Dec 31, 2025 | 8.27 Mn |
| Dec 31, 2025 | 8.27 Mn |
| Sep 30, 2025 | 2.13 Mn |
| Sep 30, 2025 | 2.13 Mn |
| Jun 30, 2025 | -885,000.00 |
| Jun 30, 2025 | -885,000.00 |
| Mar 31, 2025 | 4.91 Mn |
| Mar 31, 2025 | 4.91 Mn |
| Dec 31, 2024 | 1.92 Mn |
| Dec 31, 2024 | 1.92 Mn |
| Sep 30, 2024 | -14.00 Mn |
| Sep 30, 2024 | -14.00 Mn |
| Jun 30, 2024 | 9.93 Mn |
| Jun 30, 2024 | 9.93 Mn |
| Mar 31, 2024 | 10.99 Mn |
| Mar 31, 2024 | 10.99 Mn |
| Dec 31, 2023 | -25.39 Mn |
| Dec 31, 2023 | -25.39 Mn |